Planta Med 2012; 78(6): 575-581
DOI: 10.1055/s-0031-1298301
Pharmacokinetic Investigations
Original Papers
© Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetics of Valerenic Acid in Rats after Intravenous and Oral Administrations

Chethan Sampath1 , Karin Haug1 , Sophia Thanei2 , Matthias Hamburger2 , Hartmut Derendorf1 , Reginald Frye3 , Veronika Butterweck1
  • 1Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
  • 2Institute of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
  • 3Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA
Further Information

Publication History

received October 7, 2011 revised January 3, 2012

accepted January 24, 2012

Publication Date:
12 March 2012 (online)

Abstract

Valerenic acid (VA), a sesquiterpenoid, is one of the major secondary bioactive metabolites of Valeriana officinalis L. Until now in vivo studies on the absorption, bioavailability, disposition, and metabolism of VA are limited. We established and validated an LC-MS/MS assay for the determination of VA in rat plasma and successfully used this method for pharmacokinetic studies in rats after intravenous (i. v.) and oral administrations. The plasma concentration-time data was analyzed by both non-compartmental and compartmental approaches using WinNonlin software. Following i. v. administration, the disposition of VA in rat plasma was biphasic, subdivided into a fast distribution and a slow elimination phase. The half-life of the distribution phase was 6–12 min, and that of the terminal elimination phase 6–46 h, indicating a possible large tissue binding. Disposition PK of valerenic acid after oral treatment was also described by a two-compartment model with a clearance (CL/F) of 2–5 L · h−1 · kg−1 and volume of distribution of (Vd) 17–20 L · kg−1. The extent of absorption (F) after oral administration was estimated to be 33.70 % with a half-life of 2.7–5 h. Dose proportionality was observed in terms of dose and AUCs, suggesting linear pharmacokinetics at the dose levels studied in rats.

References

  • 1 European Scientific Cooperative on Phytotherapy (ESCOP) . Valeriana officinalis . ESCOP Monographs. 2nd edition. Stuttgart: Thieme; 2003: 539-546
  • 2 Khom S, Baburin I, Timin E, Hohaus A, Trauner G, Kopp B, Hering S. Valerenic acid potentiates and inhibits GABAA receptors: molecular mechanism and subunit specificity.  Neuropharmacology. 2007;  53 178-187
  • 3 Khom S, Strommer B, Ramharter J, Schwarz T, Schwarzer C, Erker T, Ecker G F, Mulzer J, Hering S. Valerenic acid derivatives as novel subunit-selective GABAA receptor ligands – in vitro and in vivo characterization.  Br J Pharmacol. 2010;  161 65-78
  • 4 Trauner G, Khom S, Baburin I, Benedek B, Hering S, Kopp B. Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid.  Planta Med. 2008;  74 19-24
  • 5 Neuhaus W, Trauner G, Gruber D, Oelzant S, Klepal W, Kopp B, Noe C R. Transport of a GABAA receptor modulator and its derivatives from Valeriana officinalis L. s. l. across an in vitro cell culture model of the blood-brain barrier.  Planta Med. 2008;  74 1338-1344
  • 6 Hendriks H, Bos R, Woerdenbag H J, Koster A S. Central nervous depressant activity of valerenic acid in the mouse.  Planta Med. 1985;  51 28-31
  • 7 Murphy K, Kubin Z J, Shepherd J N, Ettinger R H. Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats.  Phytomedicine. 2010;  17 674-678
  • 8 Benke D, Barberis A, Kopp S, Altmann K H, Schubiger M, Vogt K E, Rudolph U, Mohler H. GABAA receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts.  Neuropharmacology. 2009;  56 174-181
  • 9 Chow N K, Fretz M, Hamburger M, Butterweck V. Telemetry as a tool to measure sedative effects of a valerian root extract and its single constituents in mice.  Planta Med. 2011;  77 795-803
  • 10 Anderson G D, Elmer G W, Taibi D M, Vitiello M V, Kantor E, Kalhorn T F, Howald W N, Barsness S, Landis C A. Pharmacokinetics of valerenic acid after single and multiple doses of valerian in older women.  Phytother Res. 2010;  24 1442-1446
  • 11 FDA .Guidance for industry – bioanalytical method validation. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf Accessed June 4, 2011
  • 12 Barve A, Chen C, Hebbar V, Desiderio, Saw C L, Kong A N. Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats.  Biopharm Drug Dispos. 2009;  30 356-365
  • 13 Davies M, Whitting I J. Numerical methods for non-linear optimization. New York: Academic Press; 1972
  • 14 Perry N B, Burgess E J, Lorimer S D, Klink J W. Fatty acid anilides as internal standards for high performance liquid chromatographic analyses of Valerian officinalis L. and other medicinal plants.  Phytochem Anal. 1996;  7 263-268
  • 15 Maier-Salamon A, Trauner G, Hiltscher R, Reznicek G, Kopp B, Thalhammer T, Jaeger W. Hepatic metabolism and biliary excretion of valerenic acid in isolated perfused rat livers: role of Mrp2 (Abcc2).  J Pharm Sci. 2009;  98 3839-3849

Dr. Veronika Butterweck

College of Pharmacy
Department of Pharmaceutics
University of Florida

PO Box 100494

Gainesville, FL 32610

USA

Phone: +1 35 22 73 78 59

Email: butterwk@cop.ufl.edu


Current address:
University of Applied Sciences
School of Life Sciences
Department of Pharmatechnology

Gründenstrasse 40

4132 Muttenz

Switzerland

Email: veronika.butterweck@fhnw.ch